文献速递造血干细胞移植与细胞治疗

供者年龄与亲缘关系对采用移植后环磷酰胺的T细胞充足单倍体移植临床结局的影响

Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy.
PubMed 文献 · Blood Adv · 2020-01-01

该多中心回顾性分析纳入990例采用移植后环磷酰胺(PT-Cy)的T细胞充足单倍体造血干细胞移植,评估供者年龄及非HLA因素对结局的影响。供者年龄增长与2至4级急性移植物抗宿主病(aGVHD)风险升高相关,非复发死亡(NRM)呈升高趋势(HR 1.05,P=0.057),但疾病复发风险显著降低(HR 0.92,P=0.001)且无进展生存(PFS)改善(HR 0.97,P=0.036)。作者认为年轻供者可减少aGVHD和NRM但复发风险较高,≤40岁受者不推荐父母供者尤其是母亲。

要点

  • 供者年龄增长与2至4级aGVHD风险升高相关,NRM呈升高趋势(HR 1.05,P=0.057)。
  • 供者年龄增长与疾病复发风险显著降低(HR 0.92,P=0.001)及PFS改善(HR 0.97,P=0.036)相关。
  • ≤40岁受者接受父母供者移植较同胞供者复发风险更高(HR 1.39,P<0.001),作者不推荐父母尤其母亲供者。

核心结论

  • 作者认为年轻供者可降低aGVHD和NRM发生率,但复发风险较高。
  • 作者不推荐≤40岁受者选择父母供者,尤其是母亲供者。

研究设计与样本

  • 多中心回顾性分析,纳入990例采用移植后环磷酰胺(PT-Cy)的T细胞充足单倍体造血干细胞移植。

主要发现

  • 校正供受者亲缘关系后,供者年龄增长和外周血干细胞移植物与2至4级aGVHD风险升高相关。
  • 中度至重度慢性GVHD的2年累积发生率在女性供者至男性受者及清髓性预处理后更高。
  • 供者年龄增长与非复发死亡(NRM)升高趋势相关(HR 1.05,P=0.057),与疾病复发风险显著降低(HR 0.92,P=0.001)及无进展生存(PFS)改善(HR 0.97,P=0.036)相关。
  • 受者年龄增长是总生存(OS)更差的预测因素。
  • ≤40岁患者接受父母供者移植较同胞供者复发风险更高(HR 1.39,P<0.001);供者为母亲时OS和PFS低于父亲供者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Donor selection contributes to improve clinical outcomes of T-cell-replete haploidentical stem cell transplantation (haplo-SCT) with posttransplant cyclophosphamide (PT-Cy). The impact of donor age and other non-HLA donor characteristics remains a matter of debate. We performed a multicenter retrospective analysis on 990 haplo-SCTs with PT-Cy. By multivariable analysis, after adjusting for donor/recipient kinship, increasing donor age and peripheral blood stem cell graft were associated with a higher risk of grade 2 to 4 acute graft-versus-host-disease (aGVHD), whereas 2-year cumulative incidence of moderate-to-severe chronic GVHD was higher for transplants from female donors into male recipients and after myeloablative conditioning. Increasing donor age was associated with a trend for higher nonrelapse mortality (NRM) (hazard ratio [HR], 1.05; P = .057) but with a significant reduced risk of disease relapse (HR, 0.92; P = .001) and improved progression-free survival (PFS) (HR, 0.97; P = .036). Increasing recipient age was a predictor of worse overall survival (OS). Risk of relapse was higher (HR, 1.39; P < .001) in patients aged ≤40 years receiving a transplant from a parent as compared with a sibling. Moreover, OS and PFS were lower when the donor was the mother rather than the father. Pretransplant active disease status was an invariably independent predictor of worse clinical outcomes, while recipient positive cytomegalovirus serostatus and hematopoietic cell transplant comorbidity index >3 were associated with worse OS and PFS. Our results suggest that younger donors may reduce the incidence of aGVHD and NRM, though at higher risk of relapse. A parent donor, particularly the mother, is not recommended in recipients ≤40 years.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Mariotti J, Raiola AM, Evangelista A, et al. Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. Blood Adv. 2020. PMID: 32813875. doi:10.1182/bloodadvances.2020001620

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。